T1	HMM 0 45	Safety, pharmacokinetics and pharmocodynamics
T2	HMM 858 900	5-aminolevulinic acid and porphobilinogen.
T3	HMM 2398 2536	concentrations of recombinant human porphobilinogen deaminase and titres of antibodies against recombinant human porphobilinogen deaminase
T4	HMM 2561 2624	Plasma porphobilinogen and 5-aminolevulinic acid concentrations
T5	HMM 2708 2783	Urinary porphobilinogen, 5-aminolevulinic acid and porphyrin concentrations
T6	HMM 2796 2827	plasma porphyrin concentrations
T7	HMM 2989 3011	serious adverse events
T8	HMM 3139 3201	antibodies against recombinant human porphobilinogen deaminase
T9	HMM 3225 3249	allergic manifestations.
T10	HMM 3254 3349	mean elimination half-lives of the highest doses of recombinant human porphobilinogen deaminase
T11	HMM 3471 3517	area under the plasma concentration-time curve
T12	HMM 3621 3658	plasma porphobilinogen concentrations
T13	HMM 3825 3861	plasma porphobilinogen concentration
T14	HMM 3975 4018	plasma 5-aminolevulinic acid concentrations
T15	HMM 4060 4085	porphyrin concentrations.
T16	HMM 4090 4146	corresponding concentrations of metabolites in the urine
T17	HMM 4648 4668	therapeutic efficacy
